Table 1.
Demographic and clinical features of the 29 RRMS patients of the study.
| Demographic and Clinical Features | All (n = 29) |
Active | Inactive EID (n = 19) |
|
|---|---|---|---|---|
| SD (n = 8) |
EID (n = 2) |
|||
| Age, mean (SD) | 44 (10.5) | 36.5 (9.5) | 59.5 (3.5) | 46 (9) |
| Gender (F), n (%) | 21 (72.4) | 5 (62.5) | 2 (100) | 14 (73.6) |
| BMI, mean (SD) | 23.3 (3.6) | 22 (2.7) | 21.2 (2.2) | 24 (4) |
| Serology JCV (+), n (%) | 4 (13.8) | 2 (20) | 1 (50) | 1 (5.2) |
| Time since diagnosis (y), mean (SD) | 13.5 (7.3) | 10.2 (8.2) | 23 (9.9) | 13.9 (6) |
Time under NTZ (y), mean (SD)
|
7.3 (3.7) - |
7.3 (2.3) - |
11.5 (3.5) 3.5 (3.5) |
11.2 (3.3) 6.8 (2.8) |
| Previous treatment, n (%) | 21 (72.4) | 5 (62.5) | 2 (100) | 14 (73.6) |
Activity under NTZ, n (%)
|
8 (27.5) 6 (20.6) |
6 (75) 6 (75) |
2 (100) 0 |
- - |
| EDSS, mean (SD) | 3.2 (1.9) | 2.9 (2.2) | 4.3 (2.5) | 3.2 (1.8) |
BMI: body mass index; EDSS: Expanded Disability Status Scale; EID: extended interval dose; F: female; JCV: John Cunningham virus; MRI: magnetic resonance imaging; NTZ: natalizumab; SD: standard desviation; y: years.